Caribou Biosciences

Historical price data

Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is a clinical-stage biotech focused on developing allogeneic CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company's mission is to create readily available, 'off-the-shelf' cell therapies that address the manufacturing complexities, high costs, and delays associated with personalized autologous treatments. Its strategy centers on 'armoring' these therapies through multiplex gene editing to enhance persistence and activity, with multiple Phase 1 clinical trials underway for B-cell non-Hodgkin lymphoma and multiple myeloma. Caribou aims to translate its foundational CRISPR science into transformative medicines for hematologic cancers.

Proprietary chRDNA (CRISPR hybrid RNA-DNA) genome-editing technology designed for superior specificity and complex multiplexed editing, enabling the development of armored allogeneic cell therapies.